Because the stuff in the university that we see is very early, there is quite often a requirement to package it—at least to build the first prototype to validate that the technology works, to de-risk to the point that somebody will open up a chequebook and buy something, so that they can actually be inspired that there's a product there and that at least the technical risk has been addressed.
I found from my own perspective that the Canadian receptor base is primarily dominated by SMEs, and they are risk averse. They don't have a lot of disposable resources to invest in those de-risking opportunities, so to encourage them to take that leap of faith and to license it in and move forward with it, we have to bear that weight I guess as much as possible. Then we have more likelihood of getting the technologies licensed, particularly to Canadian entities.
It's not as big a problem, quite frankly, with international companies. Of course, we do research with large U.S. and European companies, and they're quite often more amenable to licensing the technology without those de-risking opportunities. But in the Canadian context, de-risking seems to be much more important to encourage the private sector to take them on.